Aging Cells Use Mitochondria to Keep Inflammation Switched On

Senescent cells are the aging body's quiet troublemakers: they no longer divide, but they keep producing the inflammatory molecule cocktail that researchers call the senescence-associated secretory phenotype, or SASP. For years, the dominant explanation for that cocktail ran through the cytoplasm: damaged mitochondria leak mitochondrial DNA and RNA, which trips the cell's innate-immune alarm. A Nature paper from Mayo Clinic and Sanford Burnham Prebys now adds a second, independent route, one that runs through the nucleus rather than around it, and names a specific mitochondrial protein that supplies the fuel.

The new axis runs from mitochondria into the cell's gene-control machinery. Senescent cells ramp up production of acetyl-CoA, a fundamental metabolic intermediate that also donates the chemical groups cells use to mark which genes are switched on. In these cells, mitochondria are a major source of that acetyl-CoA, and the study shows that cutting the supply to chromatin (the protein-and-DNA packaging that determines which genes are accessible) is enough to dampen the SASP. "Senescent cells are metabolically active and require a specific metabolic signal to drive the SASP," first author Helene Martini, PharmD, PhD, a research fellow at Mayo Clinic, said in the institutional release. The result is a finding about how the inflammatory program is sustained, not a treatment.

The team traced the supply line to SLC25A1, a transporter that ferries citrate out of the mitochondrial matrix, where cellular machinery converts citrate into acetyl-CoA. Blocking the transporter reduced the acetyl-CoA available for chromatin modification and, in the study's experiments, lowered the SASP. Senior author João Passos, PhD, has spent years mapping how aging cells drive inflammation; his earlier work established the mitochondrial-DNA-leak axis as one trigger. The new paper argues that axis is necessary but not sufficient. The epigenetic arm is independently required, and the two together describe a fuller picture of what keeps a senescent cell inflammatory.

Aging-biology drug discovery has been sorting itself into two camps, and the new work lands squarely in the second one. Senolytics try to kill senescent cells outright; senomorphics try to rewrite what those cells secrete without removing them. The new study sharpens what "senomorphic" can mean at the molecular level. Instead of blocking one inflammatory cytokine at a time, a senomorphic aimed at SLC25A1 would, in principle, throttle the entire SASP program by cutting off the metabolic fuel that keeps the inflammatory genes open. That is a more ambitious claim than the study itself supports: the paper is preclinical, the experiments used established senescent-cell models, and SLC25A1 is a research handle, not a drug candidate.

Several open questions follow from the finding. The first is whether the same metabolic-to-epigenetic arm operates in the senescent cells that accumulate in human tissues with age, not only in the cell-culture and animal systems the team used. The second is how the two pathways (the established mtDNA-leak axis and the new SLC25A1-dependent chromatin arm) interact inside a single senescent cell, and whether one can compensate when the other is blocked. The third is whether any of the existing senomorphic programs under study elsewhere in the field already touch the SLC25A1 supply line without labeling themselves that way.

The Mayo release notes that the work was done with Sanford Burnham Prebys Medical Discovery Institute and additional collaborators, and the authors treat SLC25A1 as a target for future study rather than a near-term therapy. The field now has a second, mechanistically distinct pathway on the map, and a wider tool kit for studying what keeps senescent cells inflammatory.